Study of Carotid Artery Stenosis Through the Integration of Multimodal Imaging and Computational Fluid Dynamics
Launched by SICHUAN PROVINCIAL PEOPLE'S HOSPITAL · Mar 4, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called carotid artery stenosis, which is a narrowing of the carotid arteries that can lead to strokes. The goal of the trial is to gather detailed images and data about how blood flows through these arteries. By using advanced imaging techniques and computer analysis, researchers hope to better understand how to improve surgical treatments, such as carotid endarterectomy (a procedure to remove plaque from the artery) and carotid artery stenting (inserting a small tube to keep the artery open). This research aims to help tailor these treatments for individual patients, ultimately enhancing their recovery and quality of life.
To participate in the study, you need to be diagnosed with carotid stenosis. The trial is open to adults aged 65 to 74 years and also those between 29 and 219 years old. However, people with certain other conditions, like severe heart or kidney disease, or those with vascular malformations or aneurysms, cannot join. If eligible, participants will undergo various imaging tests and monitoring to help improve our understanding of how to better manage carotid artery stenosis and prevent strokes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1) Clinical diagnosis of carotid stenosis.
- Exclusion Criteria:
- • 1. Vascular stenosis with vascular malformations.
- • 2. Aneurysm.
- • 3. Severe heart, liver, or kidney disease.
About Sichuan Provincial People's Hospital
Sichuan Provincial People's Hospital is a leading healthcare institution in China, dedicated to advancing clinical research and improving patient care through innovative medical practices. With a robust infrastructure and a multidisciplinary team of experts, the hospital conducts a wide range of clinical trials aimed at evaluating new therapies and treatment modalities. Its commitment to high ethical standards and patient safety ensures that all research activities contribute valuable insights to the medical community, while fostering an environment of collaboration and excellence in healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chengdu, Sichuan, China
Patients applied
Trial Officials
Chunling Li, MD
Principal Investigator
Sichuan Provincial People's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported